Search Results
Feb 25, 2026, 08:51 ET AlarMax Appoints Steve Teitelbaum as Chief Technology Officer, Uniting Industry Legacy with AI-Driven Innovation
directly to President Scott Shelander and work closely with executive leadership to align technology investments with business strategy."Steve is a rare leader who combines deep technical mastery with a genuine understanding of our industry and our culture," said Scott Shelander, President of AlarMax.
More news about: AlarMax Distributors, Inc.
Feb 25, 2026, 08:41 ET One Night Out with Alan Cumming Coming to Crave and CTV Comedy Channel in Canada Thursday, February 26
Griffin, Executive Producer and VP, Television & Creative Strategy at Just For Laughs. "The special is electric — joyful, fearless, and one of those rare comedy events that feels bigger than the moment."With Cumming — Emmy-winning host of The Traitors US — at the helm, the special
More news about: Just For Laughs
Feb 25, 2026, 08:30 ET Pharma is Losing $250 Billion to Patient Dropout. Here's How to Stop It.
Recruitment & Retention | Medical Education & Field Force AmplificationTherapy areas: Oncology, Auto-Immune, Neurology, Rare & Ultra Rare Disease and complex MedTech.Ian Read Joins as Strategic AdvisorIan Read served as Pfizer's CEO (2010–2018) overseeing transformative
More news about: Hoot Health, Inc.
Feb 25, 2026, 08:30 ET Sunderstorm Accelerates Global Growth for Its KANHA Brand With Strategic Partnerships to Scale Medical-Grade Cannabis Products Across Europe and Australia
FuGu HoldingsRooted deeply in the culture and legacy of cannabis, FuGu Holdings is redefining the Australian cannabis market with a focus on rare and exclusive cultivars from artisan growers around the world. Founded in 2024, FuGu Holdings has quickly become one of the leading companies domestically,
More news about: Sunderstorm
Feb 25, 2026, 08:07 ET P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments
capabilities in genomic patient identification, and enhancing the development of and access to advanced therapies in a region disproportionately affected by rare diseases. The partnership positions P4ML at the center of the rapidly expanding $25B+ global Advanced Therapy Medicinal Products (ATMP) market,
More news about: Orphan Therapeutics Accelerator
Feb 25, 2026, 08:00 ET SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDMTM, a platform that analyzes complex genomic and multimodal data and generates
More news about: SOPHiA GENETICS
Feb 25, 2026, 07:18 ET Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
this significant milestone for imsidolimab's acceptance for review by the FDA during Rare Disease Week on Capitol Hill (February 24–26, 2026), as advocates unite to promote innovation and access to treatments for rare orphan diseases like generalized pustular psoriasis.If imsidolimab is approved,
More news about: Vanda Pharmaceuticals Inc.
Feb 25, 2026, 07:15 ET Ontario court orders unprecedented $80,000 costs award against Ontario Securities Commission in MyForexFunds case
The decision follows a major ruling that ordered the return of the vast majority of business assets that had been frozen since August 2023.In a rare and pointed critique of the regulator, Justice Kimmel stated in her reasons: "the court has not been overly impressed with the manner in which the Commission
More news about: MyForexFunds
Feb 25, 2026, 07:05 ET REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for
More news about: REGENXBIO Inc.
Feb 25, 2026, 07:00 ET CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional for Talicia®. Cumberland has assumed responsibility for the
More news about: Cumberland Pharmaceuticals Inc.
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
the discovery and initial characterization of ATX-01 (formerly known as X82108), ARTHEx's lead therapeutic candidate in clinical testing for DM1, a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. ATX-01 is an anti-miR oligonucleotide designed to inhibit microRNA23b (miR-23b), which
More news about: ARTHEx Biotech
Feb 25, 2026, 00:02 ET Children's Hospital of Philadelphia Marks One-Year Anniversary of World's First Personalized CRISPR Gene Therapy for Child with Rare Genetic Disease
collaboration with the Rare Disease Congressional Caucus and the Personalized Medicine Caucus, highlighting the need for sustained federal funding for pediatric research and policies that expand access to personalized gene therapies."As KJ's parents, we want to put a human face on rare diseases," said
More news about: Children's Hospital of Philadelphia
Feb 24, 2026, 20:57 ET Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 24, 2026, 18:52 ET QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm
N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 24, 2026, 17:54 ET Charles Zhang and Lynn Chen-Zhang Named Recipients of the 2026 Ellis Island Medal of Honor
principles, the honor is awarded solely on the basis of individual merit and societal contribution. It is not conferred jointly. While there have been rare instances in which spouses have each been recognized, such cases remain exceptional and reflect independent accomplishments and impact.Mr. Zhang
More news about: Zhang Financial
Feb 24, 2026, 16:23 ET Jonathan De Armas From De Armas Law Named "Attorney of the Year" by Orlando Style Magazine
jury trial. He later moved into civil practice, joining one of Florida's largest insurance defense firms and then a plaintiff's practice, gaining a rare dual perspective on how insurers evaluate, defend, and resolve claims.Founding De Armas Law: In 2019, Jonathan De Armas opened his own
More news about: De Armas Law Firm
Feb 24, 2026, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
epilepsy and narcolepsy, respectively. In parallel, we continue to advance our pipeline and pursue a corporate development strategy aligned with our rare disease focus that supports durable growth and long-term value creation for patients and shareholders.""Jazz had a transformative year across
More news about: Jazz Pharmaceuticals plc
Feb 24, 2026, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
epilepsy and narcolepsy, respectively. In parallel, we continue to advance our pipeline and pursue a corporate development strategy aligned with our rare disease focus that supports durable growth and long-term value creation for patients and shareholders.""Jazz had a transformative year across
More news about: Jazz Pharmaceuticals plc
Feb 24, 2026, 16:05 ET Lucid Announces Fourth Quarter and Full Year 2025 Financial Results
products and services and cancellation of orders for Lucid's vehicles; risks related to prices and availability of commodities and components, including rare-earth minerals, semiconductors and their related products, and other materials, Lucid's supply chain, logistics, inventory management and quality control,
More news about: Lucid Group
Feb 24, 2026, 16:03 ET Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
IMAAVY® produced a rapid and durable hemoglobin responsea in wAIHACurrently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-threatening disease in which pathogenic immunoglobulin (IgG) autoantibodies attach to and destroy red blood cells, leading to debilitating
More news about: Johnson & Johnson
Feb 24, 2026, 16:01 ET AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.Amgen has been
More news about: Amgen
Feb 24, 2026, 13:31 ET Holland America Line's 2027-2028 South America & Antarctica Season Showcases Longer, Immersive Voyages
(Quito), Ecuador, and Callao (Lima), Peru, and includes calls across California, Mexico, Guatemala, Costa Rica, Ecuador, Peru and Chile — providing rare opportunities such as crossing the Equator and visiting Machu Picchu, along with meaningful time in vibrant coastal cities.Guests trace the Pacific
More news about: Holland America Line
Feb 24, 2026, 12:26 ET Cox Business Teams Up with Best-Selling Author Gene Marks for "The AI Business Playbook"
to shift from early learning to strategic adoption.Avoid expensive AI mistakes. Discover why widespread AI agent adoption is still rare, and how to invest in solutions that deliver real ROI.Keep employees productive and engaged. Learn effective strategies for rolling out
More news about: Cox Communications
Feb 24, 2026, 12:15 ET Illumina launches TruPath Genome, setting a new standard in genomic insight
TruPath Genome, we are pushing the boundaries of genomics and setting a new standard for genetic and rare disease research," said Steve Barnard, PhD, chief technology officer of Illumina. "In rare disease, you're often looking for a variant needle in a genomic haystack—and comprehensiveness, accuracy,
More news about: Illumina, Inc.
Feb 24, 2026, 11:32 ET Marble Capital Continues Expansion, Hires Doug Goff to Lead Open-End Strategy
investors through up and down cycles, and Doug's hire will help us execute on this goal."Goff said, "Joining the team at Marble Capital is a rare opportunity to join a best-in-class real estate investment manager and partner with an exceptional team with shared values. Marble is unique in offering
More news about: Marble Capital